Spiriva as good as Serevent in asthma study

September 19, 2010 By ALICIA CHANG , AP Science Writer

(AP) -- Researchers say they've found a possible new treatment for adults with hard-to-control asthma. Their discovery, however, came at a price.

Scientists of a U.S. government-funded study had to spend nearly $1 million of taxpayers' money after British drugmaker PLC declined to donate its asthma drug and look-alike dummy medicine for the study, which compared two other treatments.

Editors of the , which published the study, chastised Glaxo, saying its actions made the research harder and more expensive to do. aren't required to supply their medicines for study, but they often do.

"In the end, the study results provided the truth" - the drug, Spiriva, was as good as Glaxo's Serevent, they wrote. The study was published online Sunday to coincide with a presentation at a medical meeting in Barcelona, Spain.

About 300 million people worldwide suffer from asthma. In the U.S., 22 million Americans have asthma, which kills about 4,000 a year. For people who can't control their asthma with inhaled steroid medicine, current guidelines call for doubling the dose or adding a different drug that relaxes the muscles to help patients breathe.

Researchers tested three inhaled treatments: doubling the steroid dose, adding Glaxo's Serevent or adding Boehringer Ingelheim's Spiriva, which is approved for and other chronic lung conditions, but not asthma.

The study involved 210 people whose asthma was not well controlled. They took each drug for 14 weeks with two-week breaks in between treatment.

Researchers found Spiriva worked better than a double steroid dose and was as effective as Serevent. When the study first began, patients on average had 77 asthma-free days a year - days in which they had no symptoms and did not have to use their rescue inhaler.

Doubling the steroid medicine gave patients an extra 19 asthma-free days; taking Spiriva gave them an additional 48 days with no symptoms, and taking Serevent gave them an extra 51 days.

Spiriva is a promising alternative asthma treatment and some doctors are already using it in people who don't respond to steroid medicine, but more study on drug safety is needed, Dr. Lewis Smith of Northwestern University wrote in an accompanying editorial.

Two years ago, safety concerns were raised with Spiriva inhalers. But the Food and Drug Administration earlier this year said recent data do not show a connection between a popular inhaler and previously reported risks of stroke, heart attack and death.

The $5.3 million study was funded by the National Heart, Lung and Blood Institute. Teva Pharmaceutical Industries supplied the inhaled steroid medicine and Boehringer Ingelheim provided Spiriva. Both companies also donated matching placebos. Researchers bought Glaxo's Serevent.

Glaxo declined to participate because Spiriva is not approved for treating asthma. The company also "lacked adequate information in this case to understand what the impact would be on patients in the trial," said company spokeswoman Mary Anne Rhyne.

The study's leader, Dr. Stephen Peters of Wake Forest University Baptist Medical Center, said that since his team did not have access to Glaxo's drug, they bought it from a third-party supplier and hired another company to make the placebo - at a cost of $900,000.

Peters said it's harder to get drug companies to donate their medicine for research compared with a decade ago.

"Now more drug companies are more likely to ponder whether a trial could help them in the marketplace" and decline to provide their products for studies, Peter said.

Peters has received lecture fees from Teva. Several other researchers on the team reported ties with Glaxo and other drug companies.

More information: The New England Journal of Medicine: http://www.nejm.org


Related Stories

Recommended for you

Opioid addiction treatment behind bars reduced post-incarceration overdose deaths in RI

February 14, 2018
A treatment program for opioid addiction launched by the Rhode Island Department of Corrections was associated with a significant drop in post-incarceration drug overdose deaths and contributed to an overall drop in overdose ...

Heroin vaccine blocks lethal overdose

February 14, 2018
Scientists at The Scripps Research Institute (TSRI) have achieved a major milestone toward designing a safe and effective vaccine to both treat heroin addiction and block lethal overdose of the drug. Their research, published ...

Study shows NIH spent >$100 billion on basic science for new medicines

February 12, 2018
Federally funded research contributed to the science underlying all new medicines approved by the FDA over the past six years, according to a new study by Bentley University.

Opioid use increases risk of serious infections

February 12, 2018
Opioid users have a significantly increased risk of infections severe enough to require treatment at the hospital, such as pneumonia and meningitis, as compared to people who don't use opioids.

Placebo pills prescribed honestly help cancer survivors manage symptoms

February 9, 2018
Long after cancer treatment ends, many continue to deal with one particular symptom that refuses to go away: fatigue. In a new study, researchers at the University of Alabama at Birmingham and Harvard Medical School have ...

Multinational companies continue to produce unregulated antibiotics in India

February 5, 2018
Millions of unapproved antibiotics are being sold in India, according to a new study by researchers at Queen Mary University of London and Newcastle University.


Adjust slider to filter visible comments by rank

Display comments: newest first

1 / 5 (2) Sep 19, 2010
"and hired another company to make the placebo - at a cost of $900,000"
I'm not entirely comfortable with this.
not rated yet Sep 19, 2010
"and hired another company to make the placebo - at a cost of $900,000"
I'm not entirely comfortable with this.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.